Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

1.9K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.9K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.4K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.4K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.2K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

962
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
962
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

672
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
672

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Network and receptor architectures shape brain morphometry in addiction.

medRxiv : the preprint server for health sciences·2026
Same author

Reward learning and attention in risky alcohol use: Absence of Pavlovian influences but altered response bias in high-risk drinkers.

Behavioural brain research·2026
Same author

Replication of individual differences in the Pirates and Planets conditioned punishment task, but no correspondence to behavior in a non-clinical sample.

Journal of behavior therapy and experimental psychiatry·2026
Same author

Individual differences in resilience to alcohol advertising: Two processing biases during advert viewing predict interindividual variation in postviewing craving and consumption.

Alcohol, clinical & experimental research·2026
Same author

Attention to alcohol advertising causes elevated consumption via increased alcohol-related craving.

Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors·2026
Same author

Mental health symptom profiles and temporal trends in Dutch young people's social and emotional wellbeing and suicidality, 2017-2023.

Journal of affective disorders·2025

Related Experiment Video

Updated: Mar 2, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

36.1K

Speaking fluently with baclofen?

Esther Beraha1, Pieter Bodewits2, Wim van den Brink3

  • 1Department of Psychology, Universiteit van Amsterdam, Amsterdam, The Netherlands.

BMJ Case Reports
|May 13, 2017
PubMed
Summary

Baclofen shows promise for alcohol dependence (AD) treatment. This case study also observed baclofen effectively reduced stuttering symptoms, suggesting a potential new therapeutic application.

Keywords:
Alcohol-related disordersDrugs misuse (including addiction)Pharmacology and therapeuticsPsychiatryTherapeutic indications

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

36.1K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Alcohol dependence (AD) is a significant public health issue.
  • Baclofen is investigated for AD treatment, with mixed results in clinical trials.
  • Understanding baclofen's mechanisms, including muscle relaxation, anxiety reduction, and dopaminergic effects, is crucial.

Observation:

  • A case study details successful treatment of a patient with alcohol dependence using 120 mg of baclofen daily.
  • The patient experienced a decrease in alcohol consumption.
  • Remarkably, stuttering symptoms ceased during baclofen treatment, reappeared upon discontinuation, and resolved again after reintroducing the medication.

Findings:

  • Baclofen treatment led to a significant reduction in alcohol use.
  • Baclofen administration was directly correlated with the cessation of stuttering.
  • Discontinuation and re-administration of baclofen mirrored the on-off pattern of stuttering symptoms.

Implications:

  • Baclofen's muscle relaxant and anxiolytic properties may benefit stuttering treatment.
  • The drug's indirect dopaminergic inhibition could play a role in modulating speech fluency.
  • Further clinical research is warranted to explore baclofen as a novel therapeutic agent for stuttering.